CHMP Delivers More Good News For Sanofi's Dupixent
Executive Summary
The European committee has adopted a positive opinion for Regeneron-partnered Dupixent recommending approval to include adolescents aged 12 to 17 with atopic dermatitis.
You may also be interested in...
Dupixent And Vaccines Dominate As Sanofi Profits Rise
Sales of Praluent and Eloctate disappointed but the promise of further growth for big-selling Dupixent augurs well for the French firm's future.
Lilly/Incyte’s Olumiant Breezes Ahead of JAK Pack In Atopic Dermatitis
Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.